Subscribe

Thomas Willemsen

Articles by Thomas Willemsen

Thomas Willemsen

Targeting Hematological Malignancies With Autologous and Allogeneic Cell Therapies

ByThomas Willemsen

November 22nd 2022

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

Latest Updated Articles

Targeting Hematological Malignancies With Autologous and Allogeneic Cell Therapies
Published: November 22nd 2022 | Updated:

Trending on CGTlive®

Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks

Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years

CGTLive®’s Weekly Rewind – October 17, 2025

© 2025 MJH Life Sciences^®

All rights reserved.